Great West Life Assurance Co. Can Continues to Hold Holdings in TG Therapeutics, Inc. (TGTX)

Great West Life Assurance Co. Can held its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,839 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Great West Life Assurance Co. Can’s holdings in TG Therapeutics were worth $108,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Legal & General Group Plc boosted its position in shares of TG Therapeutics by 4.1% in the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 384 shares during the period. Bank of America Corp DE boosted its position in shares of TG Therapeutics by 11.0% in the first quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock valued at $164,000 after acquiring an additional 1,395 shares during the period. American International Group Inc. boosted its position in shares of TG Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 22,681 shares of the biopharmaceutical company’s stock valued at $264,000 after acquiring an additional 1,500 shares during the period. UBS Group AG boosted its position in shares of TG Therapeutics by 34.4% in the first quarter. UBS Group AG now owns 14,606 shares of the biopharmaceutical company’s stock valued at $171,000 after acquiring an additional 3,736 shares during the period. Finally, Teachers Advisors LLC boosted its position in shares of TG Therapeutics by 7.1% in the first quarter. Teachers Advisors LLC now owns 75,432 shares of the biopharmaceutical company’s stock valued at $879,000 after acquiring an additional 5,000 shares during the period. 49.89% of the stock is owned by institutional investors.

TG Therapeutics, Inc. (NASDAQ:TGTX) opened at 11.50 on Wednesday. TG Therapeutics, Inc. has a 12 month low of $4.10 and a 12 month high of $15.35. The company’s market capitalization is $716.57 million. The company has a 50-day moving average price of $11.50 and a 200 day moving average price of $11.35.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.01. TG Therapeutics had a negative return on equity of 154.02% and a negative net margin of 68,806.59%. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. On average, equities research analysts forecast that TG Therapeutics, Inc. will post ($1.84) EPS for the current fiscal year.

Several equities research analysts have recently weighed in on the company. FBR & Co reissued a “buy” rating on shares of TG Therapeutics in a research report on Saturday, June 17th. Zacks Investment Research cut TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. BidaskClub cut TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Jefferies Group LLC reissued a “buy” rating and issued a $23.00 price objective on shares of TG Therapeutics in a research report on Monday, June 5th. Finally, ValuEngine raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $25.40.

COPYRIGHT VIOLATION WARNING: “Great West Life Assurance Co. Can Continues to Hold Holdings in TG Therapeutics, Inc. (TGTX)” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/20/great-west-life-assurance-co-can-continues-to-hold-holdings-in-tg-therapeutics-inc-tgtx.html.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply